Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug VIS171 enters human trials for lupus, hair loss, and kidney disease

NCT ID NCT06799520

Ongoing Disease control Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This early-stage trial tests a new drug called VIS171 in 30 people with lupus, alopecia areata, or a kidney condition called FSGS. The main goal is to check safety and how the body handles the drug. Participants receive VIS171 as a shot under the skin, alongside their usual care, and are followed for up to a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
VIS171
What this could lead to
If successful, this could point toward a new treatment option for autoimmune diseases like lupus, alopecia areata, and certain kidney conditions.
What could go wrong
This is an early Phase 1 trial with only 30 people, so it is primarily checking safety. It may not show clear benefit, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA(AA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata focal segmental glomerulosclerosis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA(AA) IMMUNE-MEDIATED FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

  • Visterra Investigational Site

    Sofia, 1404, Bulgaria

  • Visterra Investigational Site

    Chisinau, MD-2025, Moldova

  • Visterra Investigational Site

    Bucharest, 11658, Romania

  • Visterra Investigational Site

    Cluj-Napoca, 40006, Romania

  • Visterra Investigational Site

    Barcelona, 8035, Spain

  • Visterra Investigational Site

    Granada, 18014, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.